

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): May 1, 2024**

**Corteva, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**  
(State or other jurisdiction  
of Incorporation)

**001-38710**  
(Commission  
File Number)

**82-4979096**  
(I.R.S. Employer  
Identification No.)

**9330 Zionsville Road,  
Indianapolis, Indiana 46268  
974 Centre Road,  
Wilmington, Delaware 19805**  
(Address of principal executive offices)(Zip Code)

**(833) 267-8382**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Common Stock, par value \$0.01 per share	CTVA	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

Item 2.02 Results of Operations and Financial Condition

On May 1, 2024, Corteva, Inc. (the "Company") announced its consolidated financial results for the quarter ended March 31, 2024. A copy of the Company's press release and financial statement schedules are furnished herewith on Form 8-K as Exhibits 99.1 and 99.2, respectively. The information contained in this report, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section. In addition, the information contained in this report shall not be deemed to be incorporated by reference into any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

<a href="#">99.1</a>	Press Release dated May 1, 2024
<a href="#">99.2</a>	Financial Statement Schedules dated May 1, 2024
104	The cover page from the Company's Current Report on Form 8-K, formatted in Inline XBRL

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORTEVA, INC.  
(Registrant)

*/s/ Brian Titus*

---

Brian Titus  
Vice President and Controller

May 1, 2024

## Corteva Reports First Quarter 2024 Results, Reaffirms 2024 Guidance

- 1Q results in line with expectations and mostly constructive ag economy
- Strength of Seed performance demonstrates global demand for top technology
- Crop Protection declines reflect just-in-time purchases and residual inventory imbalances
- FY guidance unchanged, 2024 outlook supported by controllable levers

INDIANAPOLIS, IN, May 1, 2024 – Corteva, Inc. (NYSE: CTVA) (“Corteva” or the “Company”) today reported financial results for the three months ended March 31, 2024.

### 1Q 2024 Results Overview

	Net Sales	Income from Cont. Ops (After Tax)	EPS
<b>GAAP</b> vs. 1Q 2023	<b>\$4.49B</b> (8)%	<b>\$376M</b> (38)%	<b>\$0.53</b> (37)%
	Organic <sup>1</sup> Sales	Operating EBITDA <sup>1</sup>	Operating EPS <sup>1</sup>
<b>NON-GAAP</b> vs. 1Q 2023	<b>\$4.58B</b> (6)%	<b>\$1.03B</b> (16)%	<b>\$0.89</b> (23)%

### First Quarter 2024 Highlights

- First quarter 2024 net sales decreased 8% versus prior year. Organic<sup>1</sup> sales decreased 6% in the same period.
- Seed net sales grew 2% and organic<sup>1</sup> sales increased 5%. Price was up 6% globally, led by continued execution on the Company’s price for value strategy and favorable product mix. Volume growth in North America from higher corn deliveries was offset by delayed demand in EMEA<sup>2</sup> due to unfavorable weather.
- Crop Protection net sales decreased 20% and organic<sup>1</sup> sales declined 21%, on expected industry headwinds globally. Volume declines were against a strong prior year comparison and primarily due to farmer purchases closer to application window, as well as weather and destocking impacts in EMEA<sup>2</sup>. Price was down 3% due to a competitive environment in most regions.
- GAAP income and earnings per share (EPS) from continuing operations were \$376 million and \$0.53 per share for the first quarter 2024, respectively.
- Operating EBITDA<sup>1</sup> and Operating EPS<sup>1</sup> were \$1.03 billion and \$0.89 per share for the first quarter 2024, respectively.
- The Company reaffirmed full-year 2024 guidance<sup>3</sup> and expects net sales in the range of \$17.4 billion to \$17.7 billion. Operating EBITDA<sup>1</sup> is expected to be in the range of \$3.5 billion to \$3.7 billion. Operating EPS<sup>1</sup> is expected to be in the range of \$2.70 to \$2.90 per share. Cash provided by operating activities – continuing operations is expected to be in the range of \$2.1 billion to \$2.6 billion. Free Cash Flow<sup>1</sup> is expected to be in the range of \$1.5 billion to \$2.0 billion. The Company plans to repurchase approximately \$1.0 billion shares in 2024.

(\$ in millions, except where noted)	1Q 2024	1Q 2023	% Change	% Organic <sup>1</sup> Change
<b>Net Sales</b>	<b>\$4,492</b>	<b>\$4,884</b>	<b>(8)%</b>	<b>(6)%</b>
North America	\$2,087	\$2,202	(5)%	(5)%
EMEA	\$1,588	\$1,813	(12)%	(6)%
Latin America	\$515	\$552	(7)%	(15)%
Asia Pacific	\$302	\$317	(5)%	(2)%

1. Organic Sales, Operating EPS, Operating EBITDA, and Free Cash Flow are non-GAAP measures. See page 5 for further discussion. 2. North America is defined as U.S. and Canada. EMEA is defined as Europe, Middle East and Africa. 3. The Company does not provide the most comparable GAAP measure on a forward-looking basis, except for Free Cash Flow.



"Corteva's first quarter 2024 results were largely as expected. The Seed business once again delivered exceptional performance driven by our advantaged technology and latest product line-up, reflecting farmers' continued investment in products that consistently deliver quality, yield and value.

On Crop Protection, as anticipated, we faced headwinds as the industry continues to work through residual inventory imbalances in key regions and farmers are shifting to just-in-time purchasing. We are expecting growth in the second half of 2024 driven by our differentiated portfolio, leading biologicals products and cost actions.

As a result, we are reaffirming full year 2024 guidance as well as reiterating our confidence in the previously-announced 2025 financial framework."

Chuck Magro  
Chief Executive Officer

## Seed Summary

Seed net sales were \$2.8 billion in the first quarter of 2024, up from \$2.7 billion in the first quarter of 2023. The sales increase was driven by a 6% increase in price, partially offset by a 2% unfavorable currency impact, and a 1% decline in both volume and portfolio.

Price gains were driven by strong execution globally, led by EMEA<sup>2</sup>, as farmers prioritize the use of top technology to drive higher yields. Volume gains in North America from higher corn deliveries were offset by volume declines in EMEA<sup>2</sup> due to delayed demand from unfavorable weather. Unfavorable currency impacts were led by the Turkish lira.

Segment operating EBITDA was \$748 million in the first quarter of 2024, up 15% from the first quarter of 2023. Price execution, improvement in net royalty expense, and ongoing cost and productivity actions more than offset higher commodity and production costs, and the unfavorable impact of currency. Segment operating EBITDA margin improved by approximately 300 basis points versus the prior-year period.

(\$ in millions, except where noted)	1Q 2024	1Q 2023	% Change	% Organic <sup>1</sup> Change
North America	\$1,471	\$1,323	11%	11%
EMEA	\$918	\$1,012	(9)%	-
Latin America	\$271	\$259	5%	(1)%
Asia Pacific	\$91	\$101	(10)%	(5)%
<b>Total Seed Net Sales</b>	<b>\$2,751</b>	<b>\$2,695</b>	<b>2%</b>	<b>5%</b>
<b>Seed Operating EBITDA</b>	<b>\$748</b>	<b>\$652</b>	<b>15%</b>	<b>N/A</b>



## Crop Protection Summary

Crop Protection net sales were approximately \$1.7 billion in the first quarter of 2024 compared to approximately \$2.2 billion in the first quarter of 2023. The sales decline was driven by an 18% decrease in volume, a 3% decrease in price, and a 1% unfavorable currency impact, partially offset by a 2% favorable impact from portfolio.

The decrease in volume against a strong prior year comparison was primarily due to farmer purchases closer to the application window, as well as weather and destocking impacts in EMEA<sup>2</sup>. Price declines in North America and Latin America due to competitive market dynamics were partially offset by pricing gains in EMEA to largely offset currency. Unfavorable currency impacts were primarily related to the Turkish lira.

Segment operating EBITDA was \$310 million in the first quarter of 2024, down 49% from the first quarter of 2023. Volume declines and unfavorable mix, pricing pressure, the unfavorable impact of currency, and raw material cost inflation, more than offset productivity actions. Segment operating EBITDA margin contracted by more than 970 basis points versus the prior-year period.

(\$ in millions, except where noted)	1Q 2024	1Q 2023	% Change	% Organic <sup>1</sup> Change
North America	\$616	\$879	(30)%	(30)%
EMEA	\$670	\$801	(16)%	(13)%
Latin America	\$244	\$293	(17)%	(27)%
Asia Pacific	\$211	\$216	(2)%	-
<b>Total Crop Protection Net Sales</b>	<b>\$1,741</b>	<b>\$2,189</b>	<b>(20)%</b>	<b>(21)%</b>
<b>Crop Protection Operating EBITDA</b>	<b>\$310</b>	<b>\$603</b>	<b>(49)%</b>	<b>N/A</b>

## 2024 Guidance

The global outlook for agriculture is stable with mostly constructive fundamentals in 2024. There was record-setting demand for grain, oilseeds, feed, and biofuels in 2023, and we expect that to grow in 2024. On-farm demand for inputs remains healthy and farmers continue to prioritize the need for top-tier technology, despite the normalization of commodity prices. The global Crop Protection market remains imbalanced after the significant destocking in 2023, however we expect to see market growth in the second half of 2024.

Corteva expects net sales in the range of \$17.4 billion to \$17.7 billion, growth of 2% at the mid-point. Operating EBITDA<sup>1</sup> is expected to be in the range of \$3.5 billion to \$3.7 billion, growth of 6% at the mid-point. Operating EPS<sup>1</sup> is expected to be in the range of \$2.70 to \$2.90 per share, up 4% at the mid-point, which reflects higher earnings partially offset by interest expense and a higher base tax rate. Cash provided by operating activities – continuing operations is expected to be in the range of \$2.1 billion to \$2.6 billion. Free Cash Flow<sup>1</sup> is expected to be in the range of \$1.5 billion to \$2.0 billion. The Company plans to repurchase approximately \$1.0 billion shares in 2024.

The Company is not able to reconcile its forward-looking non-GAAP financial measures, except for Free Cash Flow, to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of its control, such as Significant Items, without unreasonable effort.

## First Quarter Conference Call

The Company will host a live webcast of its first quarter 2024 earnings conference call with investors to discuss its results and outlook tomorrow, May 2, 2024, at 9:00 a.m. ET. The slide presentation that accompanies the conference call is posted on the Company's Investor Events and Presentations page. A replay of the webcast will also be available on the [Investor Events and Presentations page](#).

### About Corteva

Corteva, Inc. (NYSE: CTVA) is a publicly traded, global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world's most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the Company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at [www.corteva.com](http://www.corteva.com).

Follow Corteva on Facebook, Instagram, LinkedIn, Twitter, and YouTube.

### Cautionary Statement About Forward-Looking Statements

This report contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates," "outlook," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; environmental, social and governance ("ESG") targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva's control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva's business, results of operations and financial condition. Some of the important factors that could cause Corteva's actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of Corteva's products; (ii) failure to successfully develop and commercialize Corteva's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva's biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vi) effect of climate change and unpredictable seasonal and weather factors; (vii) failure to comply with competition and antitrust laws; (viii) effect of competition in Corteva's industry; (ix) competitor's establishment of an intermediary platform for distribution of Corteva's products; (x) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xi) effect of volatility in Corteva's input costs; (xii) risk related to geopolitical and military conflict; (xiii) risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities in connection with the separation of Corteva; (xiv) risks related to Corteva's global operations; (xv) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xvi) effect of industrial espionage and other disruptions to Corteva's supply chain, information technology or network systems; (xvii) failure of Corteva's customers to pay their debts to Corteva, including customer financing programs; (xviii) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xix) increases in pension and other post-employment benefit plan funding obligations; (xx) capital markets sentiment towards ESG matters; (xxi) risks related to pandemics or epidemics; (xxii) Corteva's intellectual property rights or defense against intellectual property claims asserted by others; (xxiii) effect of counterfeit products; (xxiv) Corteva's dependence on intellectual property cross-license agreements; and (xxv) other risks related to the Separation from DowDuPont.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the "Risk Factors" section of Corteva's Annual Report on Form 10-K, as modified by subsequent Quarterly Reports on Forms 10-Q and Current Reports on Form 8-K.



## Regulation G (Non-GAAP Financial Measures)

This earnings release includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures may include organic sales, organic growth (including by segment and region), operating EBITDA, operating EBITDA margin, operating earnings (loss) per share, and base income tax rate. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results. These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page A-5 of the Financial Statement Schedules.

Corteva is not able to reconcile its forward-looking non-GAAP financial measures, except for Free Cash Flow, to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the Company's control, such as Significant Items, without unreasonable effort. For Significant items reported in the periods presented, refer to page A-8 of the Financial Statement Schedules. Beginning January 1, 2020, the Company presents accelerated prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization represents the non-cash charge associated with the recognition of upfront payments made to Monsanto in connection with the Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. During the ramp-up period of Enlist E3™, Corteva has begun to significantly reduce the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait platform thereafter. During 2023, the company committed to restructuring activities to optimize the Crop Protection network of manufacturing and external partners, which are expected to be substantially complete in 2024. The company expects to record approximately \$180 million to \$230 million net pre-tax restructuring charges during 2024 for these activities.

Organic sales is defined as price and volume and excludes currency and portfolio and other impacts, including significant items. Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense. Operating EBITDA margin is defined as Operating EBITDA as a percentage of net sales.

Operating earnings (loss) per share is defined as "earnings (loss) per common share from continuing operations - diluted" excluding the after-tax impact of significant items, the after-tax impact of non-operating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the Company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility. Base income tax rate is defined as the effective tax rate excluding the impacts of foreign exchange gains (losses), non-operating benefits (costs), amortization of intangibles (existing as of the Separation), mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, and significant items.

The Company also uses Free Cash Flow as a non-GAAP measure to evaluate and discuss its liquidity position and ability to generate cash. Free Cash Flow is defined as cash provided by (used for) operating activities – continuing operations, less capital expenditures. We believe that Free Cash Flow provides investors with meaningful information regarding the Company's ongoing ability to generate cash through core operations, and our ability to service our indebtedness, pay dividends (when declared), make share repurchases, and meet our ongoing cash needs for our operations.

® TM Corteva Agriscience and its affiliated companies.

5/01/2024

### Media Contact

**Bethany Shively**

**+1 202-997-9438**

**[bethany.shively@corteva.com](mailto:bethany.shively@corteva.com)**

### Investor Contact

**Kim Booth**

**+1 302-485-3190**

**[kimberly.a.booth@corteva.com](mailto:kimberly.a.booth@corteva.com)**







A-1  
Corteva, Inc.  
Consolidated Statements of Operations  
(Dollars in millions, except per share amounts)

	Three Months Ended March 31,	
	2024	2023
<b>Net sales</b>	<b>\$ 4,492</b>	<b>\$ 4,884</b>
Cost of goods sold	2,550	2,771
Research and development expense	332	316
Selling, general and administrative expenses	736	726
Amortization of intangibles	177	160
Restructuring and asset related charges - net	75	33
Other income (expense) - net	(99)	(71)
Interest expense	41	31
<b>Income (loss) from continuing operations before income taxes</b>	<b>482</b>	<b>776</b>
Provision for (benefit from) income taxes on continuing operations	106	169
<b>Income (loss) from continuing operations after income taxes</b>	<b>376</b>	<b>607</b>
Income (loss) from discontinued operations after income taxes	47	(8)
<b>Net income (loss)</b>	<b>423</b>	<b>599</b>
Net income (loss) attributable to noncontrolling interests	4	4
<b>Net income (loss) attributable to Corteva</b>	<b>\$ 419</b>	<b>\$ 595</b>
<b>Basic earnings (loss) per share of common stock:</b>		
Basic earnings (loss) per share of common stock from continuing operations	\$ 0.53	\$ 0.85
Basic earnings (loss) per share of common stock from discontinued operations	0.07	(0.01)
<b>Basic earnings (loss) per share of common stock</b>	<b>\$ 0.60</b>	<b>\$ 0.84</b>
<b>Diluted earnings (loss) per share of common stock:</b>		
Diluted earnings (loss) per share of common stock from continuing operations	\$ 0.53	\$ 0.84
Diluted earnings (loss) per share of common stock from discontinued operations	0.07	(0.01)
<b>Diluted earnings (loss) per share of common stock</b>	<b>\$ 0.60</b>	<b>\$ 0.83</b>
<b>Average number of shares outstanding used in earnings (loss) per share (EPS) calculation (in millions)</b>		
Basic	700.4	712.9
Diluted	702.8	716.2

A-2  
Corteva, Inc.  
Consolidated Balance Sheets  
(Dollars in millions, except share amounts)

Assets	March 31, 2024	December 31, 2023	March 31, 2023
<b>Current assets</b>			
Cash and cash equivalents	\$ 1,505	\$ 2,644	\$ 1,646
Marketable securities	153	98	85
Accounts and notes receivable, net	7,906	5,488	8,678
Inventories	6,183	6,899	6,585
Other current assets	1,416	1,131	1,335
<b>Total current assets</b>	<b>17,163</b>	<b>16,260</b>	<b>18,329</b>
Investment in nonconsolidated affiliates	123	115	87
Property, plant and equipment	9,013	8,956	8,633
Less: Accumulated depreciation	4,807	4,669	4,362
Net property, plant and equipment	4,206	4,287	4,271
Goodwill	10,553	10,605	10,508
Other intangible assets	9,446	9,626	10,137
Deferred income taxes	551	584	508
Other assets	1,583	1,519	1,660
<b>Total Assets</b>	<b>\$ 43,625</b>	<b>\$ 42,996</b>	<b>\$ 45,500</b>
<b>Liabilities and Equity</b>			
<b>Current liabilities</b>			
Short-term borrowings and finance lease obligations	\$ 2,148	\$ 198	\$ 3,787
Accounts payable	3,606	4,280	3,957
Income taxes payable	311	174	298
Deferred revenue	2,694	3,406	2,712
Accrued and other current liabilities	2,573	2,351	2,477
<b>Total current liabilities</b>	<b>11,332</b>	<b>10,409</b>	<b>13,231</b>
Long-term debt	2,492	2,291	1,241
Other noncurrent liabilities			
Deferred income tax liabilities	753	899	1,255
Pension and other post employment benefits - noncurrent	2,453	2,467	2,242
Other noncurrent obligations	1,587	1,651	1,692
<b>Total noncurrent liabilities</b>	<b>7,285</b>	<b>7,308</b>	<b>6,430</b>
<b>Commitments and contingent liabilities</b>			
<b>Stockholders' equity</b>			
Common stock, \$0.01 par value; 1,666,667,000 shares authorized; issued at March 31, 2024 - 697,800,000; December 31, 2023 - 701,260,000; and March 31, 2023 - 710,678,000	7	7	7
Additional paid-in capital	27,468	27,748	27,844
Retained earnings (accumulated deficit)	302	(41)	487
Accumulated other comprehensive income (loss)	(3,010)	(2,677)	(2,739)
<b>Total Corteva stockholders' equity</b>	<b>24,767</b>	<b>25,037</b>	<b>25,599</b>
Noncontrolling interests	241	242	240
Total equity	25,008	25,279	25,839
<b>Total Liabilities and Equity</b>	<b>\$ 43,625</b>	<b>\$ 42,996</b>	<b>\$ 45,500</b>



A-3  
Corteva, Inc.  
**Consolidated Statement of Cash Flows**  
*(Dollars in millions, except per share amounts)*

	Three Months Ended March 31,	
	2024	2023
<b>Operating activities</b>		
Net income (loss)	\$ 423	\$ 599
(Income) loss from discontinued operations after income taxes	(47)	8
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities:		
Depreciation and amortization	307	287
Provision for (benefit from) deferred income tax	(152)	(85)
Net periodic pension and OPEB (credits) costs	41	36
Pension and OPEB contributions	(53)	(50)
Net (gain) loss on sales of property, businesses, consolidated companies, and investments	(5)	1
Restructuring and asset related charges - net	75	33
Other net loss	141	48
Changes in operating assets and liabilities, net		
Accounts and notes receivable	(2,546)	(2,705)
Inventories	618	324
Accounts payable	(615)	(907)
Deferred revenue	(700)	(685)
Other assets and liabilities	(93)	(206)
Cash provided by (used for) operating activities - continuing operations	(2,606)	(3,302)
Cash provided by (used for) operating activities - discontinued operations	(3)	(9)
Cash provided by (used for) operating activities	(2,609)	(3,311)
<b>Investing activities</b>		
Capital expenditures	(148)	(151)
Proceeds from sales of property, businesses, and consolidated companies - net of cash divested	5	21
Acquisitions of businesses - net of cash acquired	—	(1,463)
Investments in and loans to nonconsolidated affiliates	—	—
Purchases of investments	(132)	—
Proceeds from sales and maturities of investments	7	40
Proceeds from settlement of net investment hedge	—	42
Other investing activities, net	(2)	—
Cash provided by (used for) investing activities	(270)	(1,511)
<b>Financing activities</b>		
Net change in borrowings (less than 90 days)	656	3,084
Proceeds from debt	1,675	626
Payments on debt	(190)	(56)
Repurchase of common stock	(252)	(252)
Proceeds from exercise of stock options	8	7
Dividends paid to stockholders	(112)	(107)
Other financing activities, net	(19)	(28)
Cash provided by (used for) financing activities	1,766	3,274
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents	(31)	(2)
Increase (decrease) in cash, cash equivalents and restricted cash equivalents	(1,144)	(1,550)
Cash, cash equivalents and restricted cash equivalents at beginning of period	3,158	3,618
<b>Cash, cash equivalents and restricted cash equivalents at end of period</b>	<b>\$ 2,014</b>	<b>\$ 2,068</b>

A-4  
Corteva, Inc.  
Consolidated Segment Information  
(Dollars in millions, except per share amounts)

	Three Months Ended March 31,	
	2024	2023
<b>SEGMENT NET SALES - SEED</b>		
Corn	\$ 2,087	\$ 1,979
Soybean	292	269
Other oilseeds	245	301
Other	127	146
<b>Seed</b>	<b>\$ 2,751</b>	<b>\$ 2,695</b>

	Three Months Ended March 31,	
	2024	2023
<b>SEGMENT NET SALES - CROP PROTECTION</b>		
Herbicides	\$ 886	\$ 1,242
Insecticides	373	409
Fungicides	295	359
Other	187	179
<b>Crop Protection</b>	<b>\$ 1,741</b>	<b>\$ 2,189</b>

	Three Months Ended March 31,	
	2024	2023
<b>GEOGRAPHIC NET SALES - SEED</b>		
North America <sup>1</sup>	\$ 1,471	\$ 1,323
EMEA <sup>2</sup>	918	1,012
Latin America	271	259
Asia Pacific	91	101
<b>Rest of World <sup>3</sup></b>	<b>1,280</b>	<b>1,372</b>
<b>Net Sales</b>	<b>\$ 2,751</b>	<b>\$ 2,695</b>

	Three Months Ended March 31,	
	2024	2023
<b>GEOGRAPHIC NET SALES - CROP PROTECTION</b>		
North America <sup>1</sup>	\$ 616	\$ 879
EMEA <sup>2</sup>	670	801
Latin America	244	293
Asia Pacific	211	216
<b>Rest of World <sup>3</sup></b>	<b>1,125</b>	<b>1,310</b>
<b>Net Sales</b>	<b>\$ 1,741</b>	<b>\$ 2,189</b>

1. Reflects U.S. & Canada

2. Reflects Europe, Middle East, and Africa

3. Reflects EMEA, Latin America, and Asia Pacific

A-5  
Corteva, Inc.  
Reconciliation of Non-GAAP Measures  
(Dollars in millions, except per share amounts)

	Three Months Ended March 31,	
	2024	
<b>Net Sales (GAAP)</b>	\$	4,492
Add: Impacts from Currency and Portfolio		84
<b>Organic Sales (Non-GAAP)</b>	\$	4,576
	Three Months Ended March 31,	
	2024	2023
<b>OPERATING EBITDA</b>		
Seed	\$ 748	\$ 652
Crop Protection	310	603
Corporate Expenses	(24)	(24)
<b>Operating EBITDA (Non-GAAP)</b>	\$ 1,034	\$ 1,231
	Three Months Ended March 31,	
	2024	2023
<b>RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS AFTER INCOME TAXES TO OPERATING EBITDA</b>		
<b>Income (loss) from continuing operations after income taxes (GAAP)</b>	\$ 376	\$ 607
Provision for (benefit from) income taxes on continuing operations	106	169
<b>Income (loss) from continuing operations before income taxes (GAAP)</b>	482	776
Depreciation and amortization	307	287
Interest income	(35)	(40)
Interest expense	41	31
Exchange (gains) losses <sup>1</sup>	59	36
Non-operating (benefits) costs <sup>2</sup>	52	43
Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	1	15
Significant items (benefit) charge <sup>3</sup>	127	83
<b>Operating EBITDA (Non-GAAP)</b>	\$ 1,034	\$ 1,231

1. Refer to page A-12 for pre-tax and after tax impacts of exchange (gains) losses.
2. Non-operating (benefits) costs consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy businesses and sites of Historical DuPont. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense.
3. Refer to page A-8 for pre-tax and after tax impacts of significant items.



A-6  
Corteva, Inc.  
Reconciliation of Non-GAAP Measures  
(Dollars in millions, except per share amounts)

**PRICE - VOLUME - CURRENCY ANALYSIS**

REGION	Q1 2024 vs. Q1 2023				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change <sup>1</sup> (Non-GAAP)		Price & Product Mix	Volume	Currency	Portfolio / Other
	\$	%	\$	%				
North America	\$ (115)	(5)%	\$ (119)	(5)%	—%	(5)%	—%	—%
EMEA <sup>2</sup>	(225)	(12)%	(103)	(6)%	7%	(13)%	(5)%	(1)%
Latin America	(37)	(7)%	(81)	(15)%	(4)%	(11)%	4%	4%
Asia Pacific	(15)	(5)%	(5)	(2)%	1%	(3)%	(4)%	1%
Rest of World	(277)	(10)%	(189)	(7)%	4%	(11)%	(3)%	—%
Total	\$ (392)	(8)%	\$ (308)	(6)%	3%	(9)%	(2)%	—%

**SEED**

	Q1 2024 vs. Q1 2023				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change <sup>1</sup> (Non-GAAP)		Price & Product Mix	Volume	Currency	Portfolio / Other
	\$	%	\$	%				
North America	\$ 148	11%	\$ 147	11%	3%	8%	—%	—%
EMEA <sup>2</sup>	(94)	(9)%	2	—%	10%	(10)%	(5)%	(4)%
Latin America	12	5%	(2)	(1)%	6%	(7)%	6%	—%
Asia Pacific	(10)	(10)%	(5)	(5)%	8%	(13)%	(5)%	—%
Rest of World	(92)	(7)%	(5)	(1)%	9%	(10)%	(3)%	(3)%
Total	\$ 56	2%	\$ 142	5%	6%	(1)%	(2)%	(1)%

**CROP PROTECTION**

	Q1 2024 vs. Q1 2023				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change <sup>1</sup> (Non-GAAP)		Price & Product Mix	Volume	Currency	Portfolio / Other
	\$	%	\$	%				
North America	\$ (263)	(30)%	\$ (266)	(30)%	(5)%	(25)%	—%	—%
EMEA	(131)	(16)%	(105)	(13)%	4%	(17)%	(4)%	1%
Latin America	(49)	(17)%	(79)	(27)%	(13)%	(14)%	3%	7%
Asia Pacific	(5)	(2)%	—	—%	(2)%	2%	(3)%	1%
Rest of World	(185)	(14)%	(184)	(14)%	(1)%	(13)%	(2)%	2%
Total	\$ (448)	(20)%	\$ (450)	(21)%	(3)%	(18)%	(1)%	2%

A-7  
Corteva, Inc.  
Reconciliation of Non-GAAP Measures  
(Dollars in millions, except per share amounts)

**SEED PRODUCT LINE**

	Q1 2024 vs. Q1 2023				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change <sup>1</sup> (Non-GAAP)		Price & Product Mix	Volume	Currency	Portfolio / Other
	\$	%	\$	%				
Corn <sup>2</sup>	\$ 108	5 %	\$ 149	8 %	7 %	1 %	(2)%	(1)%
Soybeans	23	9 %	23	9 %	2 %	7 %	— %	— %
Other oilseeds <sup>2</sup>	(56)	(19)%	(9)	(3)%	10 %	(13)%	(7)%	(9)%
Other	(19)	(13)%	(21)	(14)%	(1)%	(13)%	1 %	— %
<b>Total</b>	<b>\$ 56</b>	<b>2 %</b>	<b>\$ 142</b>	<b>5 %</b>	<b>6 %</b>	<b>(1)%</b>	<b>(2)%</b>	<b>(1)%</b>

**CROP PROTECTION PRODUCT LINE**

	Q1 2024 vs. Q1 2023				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change <sup>1</sup> (Non-GAAP)		Price & Product Mix	Volume	Currency	Portfolio / Other
	\$	%	\$	%				
Herbicides	\$ (356)	(29)%	\$ (355)	(29)%	(4)%	(25)%	— %	— %
Insecticides	(36)	(9)%	(16)	(4)%	1 %	(5)%	(5)%	— %
Fungicides	(64)	(18)%	(57)	(16)%	(1)%	(15)%	(2)%	— %
Other	8	4 %	(22)	(12)%	(4)%	(8)%	(2)%	18 %
<b>Total</b>	<b>\$ (448)</b>	<b>(20)%</b>	<b>\$ (450)</b>	<b>(21)%</b>	<b>(3)%</b>	<b>(18)%</b>	<b>(1)%</b>	<b>2 %</b>

- Organic sales is defined as price and volume and excludes currency and portfolio and other impacts, including significant items.
- Other during the three months ended March 31, 2023 includes the revenue recognized relating to seed sales associated with the Russia Exit. Refer to schedule A-8 for further detail on significant items.

A-8  
Corteva, Inc.  
Significant Items  
(Dollars in millions, except per share amounts)

SIGNIFICANT ITEMS BY SEGMENT (PRE-TAX)

	Three Months Ended March 31,	
	2024	2023
Seed	\$ (16)	\$ (6)
Crop Protection	(97)	(71)
Corporate	(14)	(6)
Total significant items before income taxes	<u>\$ (127)</u>	<u>\$ (83)</u>

SIGNIFICANT ITEMS - PRE-TAX, AFTER TAX, AND EPS IMPACTS

	Pre-tax		After tax <sup>5</sup>		(\$ Per Share)	
	2024	2023	2024	2023	2024	2023
	<u>1st Quarter</u>					
Restructuring and asset related charges, net <sup>1</sup>	\$ (75)	\$ (33)	\$ (56)	\$ (25)	\$ (0.08)	\$ (0.03)
Estimated settlement expense <sup>2</sup>	(54)	(49)	(41)	(37)	(0.06)	(0.05)
Inventory write-offs <sup>3</sup>	—	(4)	—	(4)	—	(0.01)
Gain (loss) on sale of assets and equity investments <sup>3</sup>	4	3	3	1	0.01	—
Seed sale associated with Russia Exit <sup>3</sup>	—	19	—	14	—	0.02
Acquisition-related costs <sup>4</sup>	(2)	(19)	(1)	(17)	—	(0.02)
1st Quarter — Total	<u>\$ (127)</u>	<u>\$ (83)</u>	<u>\$ (95)</u>	<u>\$ (68)</u>	<u>\$ (0.13)</u>	<u>\$ (0.09)</u>

1. First quarter 2024 includes restructuring and asset related benefits (charges) of \$(75). The charges primarily relate to a \$(55) charge associated with the Crop Protection Operations Strategy Restructuring Program and a \$(20) charge related to non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits.

First quarter 2023 includes restructuring and asset related benefits (charges) of \$(33). The charges primarily relate to a \$(11) charge associated with the 2022 Restructuring Actions and a \$(16) charge related to non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits.

2. First quarter 2024 and 2023 included estimated Lorsban® related charges of \$(54) and \$(49), respectively.

3. First quarter 2024 includes a benefit of \$4 relating related to the 2022 Restructuring Actions consisting of a gain on the sale of assets. First quarter 2023 includes a benefit of \$19 relating to the sale of seeds already under production in Russia when the decision to exit the country was made and that the Company was contractually required to purchase, which consisted of \$41 of net sales and \$22 of cost of goods sold. First quarter 2023 also includes a benefit (charge) of \$(11) and \$(4) associated with activities related to the 2022 Restructuring Actions consisting of a loss on the sale of the Company's interest in an equity investment and inventory write-offs.

4. First quarter 2024 and 2023 includes acquisition-related costs relating to third-party integration costs associated with the completed acquisitions of Stoller and Symborg. The first quarter 2023 also includes transaction costs and the recognition of the inventory fair value step-up.

5. Unless specifically addressed in the notes above, the income tax effect on significant items was calculated based upon the enacted laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.



A-9  
**Corteva, Inc.**  
**Reconciliation of Non-GAAP Measures**  
*(Dollars in millions, except per share amounts)*

**Operating Earnings (Loss) Per Share (Non-GAAP)**

Operating earnings (loss) per share is defined as earnings (loss) per share from continuing operations – diluted, excluding non-operating (benefits) costs, amortization of intangibles (existing as of Separation), net unrealized gain or loss from mark-to-market activity on certain foreign currency derivative instruments that do not qualify for hedge accounting, and significant items.

	<b>Three Months Ended March,</b>			
	<b>2024</b>	<b>2023</b>	<b>2024</b>	<b>2023</b>
	<u>\$</u>	<u>\$</u>	<u>EPS (diluted)</u>	<u>EPS (diluted)</u>
<b>Net income (loss) from continuing operations attributable to Corteva (GAAP)</b>	\$ 372	\$ 603	\$ 0.53	\$ 0.84
Less: Non-operating benefits (costs), after tax <sup>1</sup>	(40)	(33)	(0.06)	(0.05)
Less: Amortization of intangibles (existing as of Separation), after tax	(117)	(118)	(0.17)	(0.16)
Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax	(1)	(11)	—	(0.02)
Less: Significant items benefit (charge), after tax	(95)	(68)	(0.13)	(0.09)
<b>Operating Earnings (Loss) (Non-GAAP)<sup>2</sup></b>	<u>\$ 625</u>	<u>\$ 833</u>	<u>\$ 0.89</u>	<u>\$ 1.16</u>

1. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy businesses and sites of Historical DuPont. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense.

2. Refer to page A-10 for the Non-GAAP reconciliation of operating EBITDA to operating earnings (loss) per share.

A-10  
Corteva, Inc.  
Operating EBITDA to Operating Earnings (Loss) Per Share  
(Dollars in millions, except per share amounts)

Operating EBITDA to Operating Earnings (Loss) Per Share

	Three Months Ended March 31,	
	2024	2023
<b>Operating EBITDA (Non-GAAP)<sup>1</sup></b>	\$ 1,034	\$ 1,231
Depreciation	(130)	(127)
Amortization of intangibles (post Separation)	(23)	(6)
Interest Income	35	40
Interest Expense	(41)	(31)
(Provision for) benefit from income taxes on continuing operations before significant items, non-operating benefits (costs), amortization of intangibles (existing as of Separation), mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, and exchange gains (losses) (Non-GAAP) <sup>1</sup>	(194)	(245)
Base income tax rate from continuing operations (Non-GAAP) <sup>1</sup>	22.1 %	22.1 %
Exchange gains (losses), after tax <sup>2</sup>	(52)	(25)
Net (income) loss attributable to non-controlling interests	(4)	(4)
<b>Operating Earnings (Loss) (Non-GAAP)<sup>1</sup></b>	\$ 625	\$ 833
Diluted Shares (in millions)	702.8	716.2
<b>Operating Earnings (Loss) Per Share (Non-GAAP)<sup>1</sup></b>	\$ 0.89	\$ 1.16

1. Refer to pages A-5 through A-7, A-9 and A-11 for Non-GAAP reconciliations.
2. Refer to page A-12 for pre-tax and after tax impacts of exchange gains (losses).

A-11  
Corteva, Inc.  
**Reconciliation of Non-GAAP Measures**  
*(Dollars in millions, except per share amounts)*

**Reconciliation of Base Income Tax Rate to Effective Income Tax Rate**

Base income tax rate is defined as the effective income tax rate less the effect of exchange gains (losses), significant items, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and non-operating (benefits) costs.

	Three Months Ended March 31,	
	2024	2023
Income (loss) from continuing operations before income taxes <b>(GAAP)</b>	\$ 482	\$ 776
Add: Significant items (benefit) charge <sup>1</sup>	127	83
Non-operating (benefits) costs	52	43
Amortization of intangibles (existing as of Separation)	154	154
Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	1	15
Less: Exchange gains (losses) <sup>2</sup>	(59)	(36)
Income (loss) from continuing operations before income taxes, significant items, non-operating (benefits) costs, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange gains (losses) <b>(Non-GAAP)</b>	<u>\$ 875</u>	<u>\$ 1,107</u>
Provision for (benefit from) income taxes on continuing operations <b>(GAAP)</b>	\$ 106	\$ 169
Add: Tax benefits on significant items (benefit) charge <sup>1</sup>	32	15
Tax expenses on non-operating (benefits) costs	12	10
Tax benefits on amortization of intangibles (existing as of Separation)	37	36
Tax benefits on mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	—	4
Tax benefits on exchange gains (losses) <sup>2</sup>	7	11
Provision for (benefit from) income taxes on continuing operations before significant items, non-operating (benefits) costs, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange gains (losses) <b>(Non-GAAP)</b>	<u>\$ 194</u>	<u>\$ 245</u>
Effective income tax rate <b>(GAAP)</b>	22.0 %	21.8 %
Significant items, non-operating (benefits) costs, amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect	0.9 %	— %
Tax rate from continuing operations before significant items, non-operating (benefits) costs, amortization of intangibles (existing as of Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	22.9 %	21.8 %
Exchange gains (losses), net effect <sup>2</sup>	(0.8)%	0.4 %
Base income tax rate from continuing operations <b>(Non-GAAP)</b>	<u>22.1 %</u>	<u>22.1 %</u>

1. See page A-8 for further detail on the Significant Items.

2. See page A-12 for further details of exchange gains (losses).

A-12  
Corteva, Inc.  
(Dollars in millions, except per share amounts)

**Exchange Gains (Losses)**

The Company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The hedging program gains (losses) are largely taxable (tax deductible) in the United States (U.S.), whereas the offsetting exchange gains (losses) on the remeasurement of the net monetary asset positions are often not taxable (tax deductible) in their local jurisdictions. The net pre-tax exchange gains (losses) are recorded in other income (expense) - net and the related tax impact is recorded in provision for (benefit from) income taxes on continuing operations in the Consolidated Statements of Operations.

	Three Months Ended March 31,	
	2024	2023
<b>Subsidiary Monetary Position Gain (Loss)</b>		
Pre-tax exchange gains (losses)	\$ 23	\$ (30)
Local tax (expenses) benefits	(10)	9
Net after tax impact from subsidiary exchange gains (losses)	\$ 13	\$ (21)
<b>Hedging Program Gain (Loss)</b>		
Pre-tax exchange gains (losses)	\$ (82)	\$ (6)
Tax (expenses) benefits	17	2
Net after tax impact from hedging program exchange gains (losses)	\$ (65)	\$ (4)
<b>Total Exchange Gain (Loss)</b>		
Pre-tax exchange gains (losses)	\$ (59)	\$ (36)
Tax (expenses) benefits	7	11
Net after tax exchange gains (losses)	\$ (52)	\$ (25)
Non-Controlling Interest Adjustment	\$ 1	\$ —
Net after-tax exchange gain (loss) attributable to Corteva	\$ (51)	\$ (25)

As shown above, the "Total Exchange Gain (Loss)" is the sum of the "Subsidiary Monetary Position Gain (Loss)" and the "Hedging Program Gain (Loss)."

A-13  
Corteva, Inc.  
Reconciliation of Non-GAAP Measures  
(Dollars in millions, except per share amounts)

**Free Cash Flow (Non-GAAP)**

Free Cash Flow is defined as cash provided by (used for) operating activities – continuing operations, less capital expenditures.

	<b>Twelve Months Ended December 31, 2023</b>	
<b>Cash provided by (used for) operating activities - continuing operations (GAAP)</b>	\$	1,809
Less: Capital expenditures		(595)
<b>Free Cash Flow (Non-GAAP)</b>	\$	1,214

	<b>Twelve Months Ended December 31, 2024<sup>1</sup></b>			
	<b>Low End</b>		<b>High End</b>	
<b>Cash provided by (used for) operating activities - continuing operations (GAAP)</b>	\$	2,130	\$	2,630
Less: Capital expenditures		(630)		(630)
<b>Free Cash Flow (Non-GAAP)</b>	\$	1,500	\$	2,000

1. This represents the reconciliation of the Company's range provided for its forward-looking non-GAAP financial measure relating to Free Cash Flow.